



**Kidney Week 2011**  
**Late-Breaking Clinical Trials Session**  
November 12 | 10:30 a.m. – 12:30 p.m.  
Hall D, Pennsylvania Convention Center

**Moderators:**

*Philip A. Marsden, MD and Marcello Tonelli, MD*

---

- 10:30 a.m. LB-OR01** **The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study** — Charmaine E. Lok<sup>1</sup>, Louise M. Moist<sup>2</sup>, Brenda Hemmelgarn<sup>3</sup>, Marcello Tonelli<sup>4</sup>, Michael Allon<sup>5</sup>, Kenneth Stanley<sup>6</sup>.  
<sup>1</sup>Toronto General Hospital and University of Toronto; <sup>2</sup>London Health Sciences Centre; <sup>3</sup>University of Calgary; <sup>4</sup>University of Alberta; <sup>5</sup>University of Alabama at Birmingham; <sup>6</sup>Harvard University.  
*Funding: Private Foundation Support; Government Support - Non-U.S.*
- 10:50 a.m. LB-OR02** **Reduced Rate of Cutaneous Squamous Cell Carcinomas after Conversion to Sirolimus-Based Immunosuppression in Stable Renal Transplant Recipients: A Randomized, Prospective, Open-Label Multicenter Study** — Judith M. Hoogendijk-van den Akker<sup>1</sup>, Paul N. Harden<sup>2</sup>, Andries Hoitsma<sup>1</sup>, Charlotte Mary Proby<sup>3</sup>, Ron Wolterbeek<sup>4</sup>, Jan Nico Bouwes Bavinck<sup>4</sup>, Johan W. De Fijter<sup>4</sup>. <sup>1</sup>Radboud University Nijmegen Medical Center; <sup>2</sup>Churchill Hospital Oxford; <sup>3</sup>Royal London Hospital; <sup>4</sup>Leiden University Medical Center. *Funding: Pharmaceutical Company Support.*
- 11:10 a.m. LB-OR03** **Multicenter Randomized Controlled Trial Comparing Efficacy of Tacrolimus to Intravenous Cyclophosphamide in Children with Steroid Resistant Nephrotic Syndrome** — Ashima Gulati, Arvind Bagga, Nephrotic Syndrome Study Group. All India Institute of Medical Sciences.  
*Funding: Government Support - Non-U.S.*
- 11:30 a.m. LB-OR04** **A Randomized Cross-Over Muticenter Trial of Mycophenolate Mofetil versus Cyclosporin A in Children with Frequently Relapsing Nephrotic Syndrome** — Uwe Querfeld, Jutta Gellermann. Charité Universitätsmedizin Berlin. *Funding: Pharmaceutical Company Support; Clinical Revenue Support.*
- 11:50 a.m. LB-OR05** **Effects of Intensive Diabetes Therapy on Glomerular Filtration Rate in Type 1 Diabetes: Results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study]** — Ian H. de Boer<sup>1</sup>, Wanjie Sun<sup>2</sup>, Patricia A. Cleary<sup>2</sup>, John M. Lachin<sup>2</sup>, Mark E. Molitch<sup>3</sup>, Michael Steffes<sup>4</sup>, Bernard Zinman<sup>5</sup>. <sup>1</sup>University of Washington; <sup>2</sup>George Washington University; <sup>3</sup>Northwestern University; <sup>4</sup>University of Minnesota; <sup>5</sup>University of Toronto. *Funding: NIDDK Support.*
- 12:10 p.m. LB-OR06** **Vitamin D Therapy and Cardiac Structure, Function, and Cardiovascular Events** — Ravi I. Thadhani. Massachusetts General Hospital. On behalf of the PRIMO Steering Committee.  
*Funding: Pharmaceutical Company Support.*